Severe Eosinophilic Asthma Recruiting Phase Trials for Mepolizumab (DB06612)

IndicationStatusPhase
DBCOND0078144 (Severe Eosinophilic Asthma)RecruitingNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03739320A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma